Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|August 18, 2015
GSK Factory in Tianjin Affected by Explosion
Author(s)Pharmaceutical Technology Editors
GSK reports no employee injuries at the facility and is assessing damage.
Advertisement
A GlaxoSmithKline factory located in Tianjin, China-near the site of an Aug. 12, 2015 warehouse explosion-was affected but no employees were injured, according to a company statement. The company has two facilities in the area.
The statement reports that the company has taken “urgent measures to ensure the safety of employees and their families, and to assess plant damage.”
GlaxoSmithKline (Tianjin) Co., Ltd. and American Tianjin Smith Kline Pharmaceutical Co., Ltd. will jointly donate one million yuan ($156,00) to the China Red Cross and is ready to provide any drugs for the recovery effort, the statement reports.
The explosion in an industrial area of the port city has claimed more than 100 lives, with more than 100 people listed as missing.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement